Advances in glaucoma treatment and management: Neurotrophic agents

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 5, 2012, Pages 2501-2505

  Chader, Gerald J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; ANTIOXIDANT; BOL 303259 X; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRIMONIDINE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR; CILIARY NEUROTROPHIC FACTOR; ELIPRODIL; FLUNARIZINE; FREE RADICAL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; IFENPRODIL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 18; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NCX 125; NEURONAL NITRIC OXIDE SYNTHASE; NEUROTROPHIC FACTOR; NEUROTROPHIN; NIMODIPINE; NITRIC OXIDE; NITRIC OXIDE REDUCTASE; PIGMENT EPITHELIUM DERIVED FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CELL ENCAPSULATION; EXCITOTOXICITY; GENE THERAPY; GLAUCOMA; GLIOSIS; HUMAN; INTRAOCULAR PRESSURE; NERVE FIBER TRANSPORT; NONHUMAN; OPTIC DISK; OPTIC NERVE; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; VISUAL IMPAIRMENT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; FREE RADICALS; GLAUCOMA; GLIOSIS; GLUTAMIC ACID; HUMANS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE;

EID: 84860699412     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9483n     Document Type: Article

References (48)

1. Pearson HE, Stoffler DJ. Retinal ganglion cell degeneration follows loss of postsynaptic target neurons in the dorsal lateral geniculate nucleus of the adult cat. Expt Neurol. 1992;116:163-171.
2. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature. 1990;347:83-86.
3. Martin KR, Quigley HA, Zack DJ, et al. Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44: 4357-4365.
4. Zhou X, Kong L, Chodosh J, Cao W. Anti-inflammatory effect of PEDF in DBA/2J mice. Mol Vis. 2009;15:438-450.
5. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Pigment epithelium-derived factor gene therapy targeting retinal ganglion cell injuries: neuroprotection against loss of function in two animal models. Hum Gene Ther. 2011;22:559-565.
6. Lambert W, Ruiz L, Wheeler L, Calkins D. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neuron. Mol Neurodegener. 2011;13:6.
7. Almasieh M, Kelly M, Casanova C, Di Polo A. Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors. Cell Death Dis. 2010;1:e27.
8. Bai Y, Sivori D, Woo SB, Neet KE, Lerner SF, Saragovi HU. During glaucoma, alpha-2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor neutralizing neuroprotection. Invest Ophthalmol Vis Sci. 2011;52:5260-5265.
9. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol. 1957;58:193-201.
10. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
11. Carter-Dawson L, Crawford ML, Harwerth RS, et al. Vitreal gluta-mate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2633-2637.
12. Honkanen RA, Baruah S, Zimmerman MB, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrec-tomy. Arch Ophthalmol. 2003;121:183-188.
13. Yucel YH, Gupta N, Zhang Q, et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol. 2006;124:217-225.
14. Wehrwein E, Thompson S, Coulibaly S, et al. Acetylcholine protection of adult pig retinal ganglion cells from glutamate-induced excitotoxicity. Invest Ophthalmol Vis. Sci. 2004;45:1531-1543.
15. Brandt SK, Weatherly ME, Ware L, Linn DM, Linn CL. Calcium preconditioning triggers neuroprotection in retinal ganglion cells. Neurosci. 2011;172;387-397.
16. Fang JH, Wang XH, Xu ZR, Jiang FG. Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cell damage. BMC Neurosci. 2010;11:31-40.
17. Crish SD, Calkins DJ. Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms. Neuroscience. 2011;176:1-11.
18. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol. 1999;43(Suppl 1): S129-S135.
19. Pang IH, Johnson EC, Jia L, et al. Evaluation of inducible NO synthetase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Invest Ophthalmol Vis Sci. 2005;46: 1313-1321.
20. Ghanem AA, Elewa AM, Arafa LF. Endothelin-1 and nitric oxide levels in patients with glaucoma. Ophthalmic Res. 2011;46:98-102.
21. Borghi V, Bastia E, Guzzetta M, et al. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog and primate models of glaucoma. J Ocul Pharmacol Ther. 2010;26:125-132.
22. Chalasani M, Radha V, Gupta V, Agarwal N, Balasubramanian D, Swarup G. A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by anti-oxidants. Invest Ophthalmol Vis Sci. 2007;48:607-614.
23. Sorkhabi R, Javadzadeh A, Rashtchizdehm N, Moharrey M. Oxida-tive DNA damage and total antioxidant status in glaucoma patients. Mol Vis. 2011;17:41-46.
24. Kang JH, Pasquale LR, Willett W, et al. Antioxidant uptake and primary open-angle glaucoma: a prospective study. Am J Epidemiol. 2003;158:337-346.
25. McElnea EM, Quill B, Docherty NG, et al. Oxidative stress, mito-chondrial dysfunction and calcium overload in human lamina cri-brosa cells from glaucoma donors. Mol Vis. 2011;17:1182-1191.
26. Sanz MM, Johnson LE, Ahuja S, Ekström PA, Romero J, van Veen T. Significant photoreceptor rescue by treatment with a combination of antioxidants in an animal model for retinal degeneration. Neu-rosci. 2007;145:1120-1129.
27. Komeima K, Rogers BS, Campochiaro PA. Antioxidants slow pho-toreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol. 2007;213:809-815.
28. Christen WG, Glynn RJ, Chew EY, Albert CM, Manson JE. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antiox-idant and Folic Acid Cardiovascular Study. Arch Internal Med. 2009;169:335-341.
29. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
30. McKinnon SJ. Glaucoma, apoptosis and neuroprotection. Curr Opin Ophthalmol. 1997;8:28-37.
31. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. Surv Ophthalmol. 1999;43(suppl 1):S151-S161.
32. Huang W, Fileta J, Dobberfuhl A, et al. Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci U S A. 2005;102:12242-12247.
33. McKernan DP, Guerin MB, O'Brien CJ, Cotter TG. A key role for calpains in retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2007;48:5420-5430.
34. Mavlyutov TA, Nickells R, Guo L. Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor. Mol Vis. 2011;17: 1034-1043.
35. Quigley HA, Cone FE, Gelman SE, Pease ME, Nguyen TD. Lack of neuroprotection against experimental glaucoma in c-Jun N-termi-nal kinase 3 knockout mice. Exp Eye Res. 2011;92:299-305.
36. Inman D, Horner P. Reactive non-proliferative gliosis predominates in a chronic mouse model of glaucoma. Glia. 2007;55:942-953.
37. Ganesh BS, Chintala SK. Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells. PLoS One. 2011;6:e18305.
38. Bosco A, Inman D, Steele M, et al. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in DBA/2J mouse model of glaucoma. Invest Ophthal-mol Vis Sci. 2008;49:1437-1446.
39. Wiggs J, Allinghan R, Hossain A, et al. Genome-wide scan for adult onset primary open angle glaucoma. Hum Mol Genet. 2000;9: 1109-1117.
40. Yang Z, Zack D. What has gene expression profiling taught us about glaucoma? Exp Eye Res. 2011;93:191-195.
41. Magharious M, D'Onofrio P, Hollander A, Zhu P, Chen J, Koeberle P. Quantitative iTRAQ analysis of retinal ganglion cell degeneration after optic nerve crush. J Proteome Res. 2011;10:3344-3362.
42. Fingert JH, Alward W, Wang K, Yorio T, Clark A. Assessment of SNPs associated with the human glucocorticoid receptor in primary open-angle glaucoma and steroid responders. Mol Vis. 2010; 16:596-601.
43. Howell G, Macalinao D, Sousa G, et al. Molecular clustering identifies complement and endothelin induction as early events in a mouse model of glaucoma. J Clin Invest. 2011;121:1429-1444.
44. McKinnon S, Schlamp C, Nickells R. Mouse models of retinal ganglion cell death and glaucoma. Exp Eye Res. 2008;88:816-824.
45. Tsolaki F, Gogaki E, Sakkias F, et al. Helicobacter pylori infection and primary open-angle glaucoma: is there a connection? Clin Ophthalmol. 2012;6:45-47.
46. Harper M, Grozdanic S, Blits B, et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011;52:4506-4515.
47. Lavik E, Kuehn M, Kwon Y. Novel drug delivery systems for glaucoma. Eye. 2011;25:578-586.
48. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31:152-181.